Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-08-23
2011-08-23
Loewe, Sun Jae Y (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S095000, C514S099000, C548S119000, C549S006000, C549S218000
Reexamination Certificate
active
08003625
ABSTRACT:
Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
REFERENCES:
patent: 3652579 (1972-03-01), Hoffer et al.
patent: 4908356 (1990-03-01), Borch et al.
patent: 4921963 (1990-05-01), Skov et al.
patent: 4945102 (1990-07-01), Suzuki et al.
patent: 5190929 (1993-03-01), Borch et al.
patent: 5233031 (1993-08-01), Borch et al.
patent: 5270330 (1993-12-01), Suzuki et al.
patent: 5306727 (1994-04-01), Borch
patent: 5403932 (1995-04-01), Borch et al.
patent: 5472956 (1995-12-01), Borch et al.
patent: 5622936 (1997-04-01), Wiessler et al.
patent: 5703080 (1997-12-01), Nakakura et al.
patent: 5750782 (1998-05-01), Denny et al.
patent: 5780585 (1998-07-01), Anlezark et al.
patent: 5872129 (1999-02-01), Denny et al.
patent: 5877158 (1999-03-01), Bosslet et al.
patent: 5985909 (1999-11-01), Denny et al.
patent: 6020315 (2000-02-01), Bosslet et al.
patent: 6130237 (2000-10-01), Denny et al.
patent: 6197760 (2001-03-01), Struck
patent: 6218519 (2001-04-01), Kenten et al.
patent: 6240925 (2001-06-01), McMillan et al.
patent: 6251933 (2001-06-01), Denny et al.
patent: 6506739 (2003-01-01), Herr et al.
patent: 6656926 (2003-12-01), Borch et al.
patent: 6855695 (2005-02-01), Lin et al.
patent: 6903081 (2005-06-01), Borch et al.
patent: 7173020 (2007-02-01), Borch et al.
patent: 7304046 (2007-12-01), Borch et al.
patent: 2003/0008850 (2003-01-01), Borch et al.
patent: 2003/0050331 (2003-03-01), Ng et al.
patent: 2003/0096743 (2003-05-01), Sender et al.
patent: 2003/0130189 (2003-07-01), Sender et al.
patent: 2004/0121940 (2004-06-01), De Groot et al.
patent: 2004/0176332 (2004-09-01), Borch et al.
patent: 2004/0254103 (2004-12-01), Lin et al.
patent: 2005/0043244 (2005-02-01), Lin et al.
patent: 2006/0258656 (2006-11-01), Matteucci
patent: 2229223 (1973-02-01), None
patent: 312 858 (1992-02-01), None
patent: 648 503 (1995-04-01), None
patent: 8-509727 (1996-10-01), None
patent: 2002-543059 (2002-12-01), None
patent: WO 94/25471 (1994-11-01), None
patent: WO 97/39007 (1997-10-01), None
patent: WO 00/64864 (2000-11-01), None
patent: WO 02/096910 (2002-12-01), None
patent: WO 03/066052 (2003-08-01), None
patent: WO 2004/085361 (2004-10-01), None
patent: WO 2004/085421 (2004-10-01), None
patent: WO 2004/087075 (2004-10-01), None
patent: WO 2005/076888 (2005-08-01), None
patent: WO 2006/057946 (2006-06-01), None
patent: WO 2008/011588 (2008-01-01), None
patent: WO 2008/076826 (2008-06-01), None
patent: WO 2008/083101 (2008-07-01), None
Misiura et al., caplus an 2002:311287.
Misiura et al., Acta Biochim. Polonica, vol. 49, 2002, pp. 169-176.
Berry et al., “5-Nitrofuran-2-ylmethyl group as a potential bioreductively activated pro-drug system,”J. Chem. Soc. Perkin Trans., 1997, 1:1147-1156.
Borch, RF, et al., “Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates,”J Med Chem, 2001, 44(1): 74-77.
Borch, RF, et al., “Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents,”J Med Chem, 2000, 43(11): 2258-2265.
De Jaeger et al., “Relationship of hypoxia to metastatic ability in rodent tumours,”Br. J. Cancer, 2001, 84(9):1280-1285.
DeGroot, et al. “Anticancer Prodrugs for Application in Monotherapy: Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors,”Current Med Chem, 2001, 8:1093-1122.
Denny, W.A., “Prodrug strategies in cancer therapy,” Eur. J. Med. Chem., 2001, 36:577-595.
Duan, Jian-Xin, “Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs,”J. Med. Chem., 2008, 51(8): 2412-2420.
Engle et al., “31P NMR Kinetic Studies of the Intra- and Intermolecular Alkylation Chemistry of Phosphoramide Mustard and Cognate N-Phosphorylated Derivatives ofN ,N-Bis(2-chlorethyl)amine1,2,”J. Med. Chem., 1982, 25:1347-1357.
Everett et al., “Bioreductively-Activated Prodrugs for Targeting Hypoxic Tissues: Elimination of Aspirin from 2-Nitroimidazole Derivatives,”Bioorganic Med.&Chem. Ltrs., 1999, 9:1267-1272.
Everett et al., “Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release,”Biochemical Pharmacology, 2002, 63:1629-1639.
Garsky Publication, “The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Greater Targeting Efficacy,”J. Med. Chem. 2001, 44(24), 4216-4224. (Abstract).
Glazman-Kusnierczyk, et al. “Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. 1. Stereodifferentiation of biological effects and selection of the most potent compounds,”Immunopharmacology and Immunotoxicology, 1992, 14(4): 883-911.
Hay et al., “A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindo1-2-YL)Carbonyl]-1,2-Dihydro-3H-Benz[E]lndole (Amino-Seco- CBI-TMI) for Use With Adept and Gdept,”Biooganic Med.&Chem. Ltrs., 1999, 9:2237-2242.
Hernick et al., “Studies on the Mechanisms of Activation of Indolequinone Phosphoramidate Prodrugs,”J. Med. Chem., 46:148-154 (2003).
Hernick, et al., “Design, Synthesis, and Biological Evaluation, of Indolequinone Phosphormamidate Prodrugs Targeted to DT-diaphorase,” 2002,J. Med Chem. 45: 3540-3548.
Kyle et al., “Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture,”Cancer Research, 2004, 64:6304-6309.
Lee, et al., “Synthesis and Hypoxia-Selective Cytotoxicity of a 2-Nitroimidazole Mustard,” Bioorganic & Med. Chem. Ltrs., 1998, 8:1741-1744.
Lin et al., “(o- andp- Nitrobenzyloxycarbobyl)—5-fluorouracil Derivatives as Potential Conjugated Bioreductive Alkylating Agents,” 1986,J. Med. Chem., 29:84-89.
Naylor et al., “Recent Advances in Bioreductive Drug Targeting,”Mini Reviews in Med. Chem., 2001, 1:17-29.
Papot, S. et al. “Design of Selectively activated anticancer prodrugs: elimination and cyclization strategies,”Curr Med Chem Anticancer Agents, 2002, 2(2): 155-85.
Parveen et al., “2-Nitroinnidazol-5-Ylmethyl as a Potential Bioreductively Activated Prodrug System: Reductively Triggered Release of the Parp Inhibitor 5-Bromoisoquinolinone,”Bioorganic Med.&Chem. Ltrs., 1999, 9:2031-2036.
Rofstad et al., “Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis,”Br. J. Cancer, 1999, 80(11):1697-1707.
Rosen et al., “Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies,”Clin. Cancer Res., 2004, 10:3689-3698.
Steinberg, G., et al., “Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents,”J Med Chem, 2001, 44(1): 69-73.
Struck, et al. “Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide,”Cancer Chemo. Pharma, 1994, 34(3): 191-6.
Studzian, et al. “Effects of alkylating metabolites of ifosfamide and its bromo analogues on DNA of HELA cells,”Biochem, Pharm. 1992, 43(5):937-943.
Wakselman, M., “1,4- and 1,6- Eliminations from Hydroxy- and Amino-Substituted Benzyl Systems: Chemical and Biochemical Applications,”Nouv. J. Chim., 1983, 7(7):439-447.
West et al., “A comparison of adriamycin and mAMSA, II. Studies with V79 and human tumour multicellular spheroids,”Cancer Chemother. Pharmacol., 1987, 20:109-114.
Workman et al., “The experimental development of bioreductive drugs and their role in cancer therapy,”Cancer and Metastasis Rev., 1993, 12:73-82.
Denny, W.A., “Nitroreductase-Based GDEPT,”Current Pharmaceutical Design, 8(15):1349-1361 (2002).
Hay, M.P. et al.,
Duan Jian-Xin
Jiao Hailong
Kaizerman Jacob
Matteucci Mark
Kilpatrick Townsend & Stockton LLP
Loewe Sun Jae Y
Threshold Pharmaceuticals, Inc.
LandOfFree
Phosphoramidate alkylator prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphoramidate alkylator prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphoramidate alkylator prodrugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2751546